Autonomix Medical closed fiscal 2026 (the year ended March 31, 2026) in a posture the company itself describes as a going concern: zero product revenue, an accumulated deficit of $67.1 million, an operating loss of $17.0 million for the year (versus $11.6 million the year before), and management's own estimate that the cash on hand at year-end - $7.0 million - would carry operations only into the fourth calendar quarter of 2026. Three months later, on July 28, 2026, a separate 8-K brought that estimate forward: cash stood at approximately $5.1 million as of that date, against a stated need of $25 million to $32 million of additional financing to reach initial commercial launch. The company does not earn, and the auditor's report carries an explicit substantial-doubt going-concern paragraph. The investment question is therefore not whether Autonomix is a going concern today - it is the cost, dilution, and conditionality of the financing bridge between today and a still-distant FDA clearance that management says could land in the 2028 timeframe. Everything in the report hangs on that bridge.
Two facts frame the rest. The first is a 1-for-21 reverse stock split that took effect on June 24, 2026; the second is a July 13, 2026 warrant inducement that reduced the exercise price of existing Series C warrants to $6.00 and brought in roughly $2.6 million of cash from a single institutional holder. The reverse split reduced the share count from 11,409,344 to approximately 542,000, and the warrant exercise then added 428,731 shares, leaving 971,043 shares outstanding as of July 28, 2026 (disclosed in the 7/28/26 8-K). At a reference price of $7.535 on August 12, 2026, that implies a market capitalization of approximately $7.3 million - a number that sits below management's own most recent estimate of cash on hand ($5.1M as of 7/28/26), so the equity is being valued at roughly $2.2 million of net cash plus an option on a clinical platform the company is not yet asking the market to price. The stock trades 77% below its post-split-adjusted 52-week high of $32.55 (set November 17, 2025) and above its 52-week low of $2.44 (set July 28, 2026, the same day the cash-and-shares 8-K reset the floor). GAAP P/E is not meaningful - the company has no product revenue, and the GAAP loss per share of $(48.80) for fiscal 2026 (post-split-restated) and $(0.36) for the most recent reported quarter, the third quarter of fiscal 2026, are not a basis for any earnings multiple.
The story the company is telling is a clinical one, not a financial one. In January 2026, at the ASCO Gastrointestinal Cancers Symposium, Autonomix presented a post-hoc subgroup analysis of its first-in-human proof-of-concept study showing that 93.75% of responding patients (N=16) moved from severe to mild or moderate pain within seven days of a transvascular radiofrequency (RF) nerve-ablation procedure, with several reporting near-elimination on a VAS pain scale. Roughly two-thirds of responding patients (N=9) maintained that level at four to six weeks, and at three months no responding patient (N=6) reported severe pain. The catch is in the qualifier "responding," in the small Ns at each time point, and in the disclosure - made in the 10-K - that as the expansion study progressed, "early clinical outcome signals in this broader cohort diverged from those seen in PoC 1 femoral access." Management responded by pausing enrollment, refining the protocol (approved by the relevant ethics committee on April 9, 2026), and refocusing on a more targeted population. The decision is responsible; it is also a tacit acknowledgment that the first-in-human signal is real but not yet consistent enough to anchor a U.S. IDE trial. The U.S. IDE program is targeted to begin in late 2026, subject to receipt of sufficient new financing.